A- A A+

Baden-Württemberg. Einheitliche Behandlungsweise gewünscht: Sozialausschuss befasst sich mit der Suchtrehabilitation von Gefangenen

Stuttgart. „Der Justizvollzug stellt kein geeignetes Umfeld zur Überwindung einer Abhängigkeitserkrankung dar.“ Dies erklärte der Vorsitzende des Ausschusses für Soziales und Integration, Rainer Hinderer (SPD), in der Sitzung am Donnerstag, 6. Dezember. Der Ausschuss hat sich auf Antrag der Grünen und der CDU mit der Suchtrehabilitation Gefangener befasst. „Eine in Haft eingeleitete medizinische Rehabilitation erhöht die Chance auf ein drogen- und straffreies Leben“, berichtete Hinderer. (Landtag von Baden-Württemberg, Pressemitteilung 132/2018, 06.12.2018)


Barriers and facilitators to hepatitis C (HCV) screening and treatment—a description of prisoners’ perspective

Des Crowley, Marie Claire Van Hout, John S. Lambert, Enda Kelly, Carol Murphy and Walter Cullen

Harm Reduction Journal 2018, 15:62, doi.org/10.1186/s12954-018-0269-z


USA. Law And Order: How the Smallest State is Defeating America’s Biggest Addiction Crisis 

Rhode Island inmates get opioid replacements while they’re locked up and it seems to be keeping them from overdosing when they get out. (Politico Magazine, USA, 25.08.2018)


Medizin im Justizvollzug - Medicine in the penal system

Dtsch Arztebl Int 2018; 115(48): 808-14; DOI: 10.3238/arztebl.2018.0808

Opitz-Welke, Annette; Lehmann, Marc; Seidel, Peter; Konrad, Norbert


Ethics and evidence on naltrexone treatment of offenders

Drugs&Alcohol Findings, UK, 2018

High im Knast: Häftlinge erhalten nur selten eine Substitutionstherapie 

Welche schadensmindernden Maßnahmen beim intravenösen Drogenkonsum im Justizvollzug könnten einer Überdosis oder der Ansteckung mit Infektionskrankheiten entgegenwirken? Das wollten Politiker der Linken-Fraktion im Bundestag von der Bundesregierung wissen. Die Antwort war wenig aussagekräftig. (Medical Tribune, 02.12.2018)


Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment.

Redman JS, Sterling RK.

Am J Gastroenterol. 2018 Jul 24. doi: 10.1038/s41395-018-0201-x. 


USA. Federal Judge Issues Groundbreaking Order to a Jail to Allow Methadone Access

A federal court judge has stated that denying medication-assisted treatment (MAT) to an incarcerated person would “likely” be found unconstitutional. The judge ordered that a plaintiff should have continued access to MAT while he is held in jail for the duration of the case. (FILTER, USA, 27.11.2018)


EU-Behörden fordern bessere Präventionund Behandlung von Infektionen in Gefängnissen

Stockholm – Gefängnisse sind auch in Europa Brutstätten für gefährliche Krankheits­erreger. Zwei EU-Behörden fordern anlässlich der internationalen Aids-Konferenz (AIDS 2018) und des bevorstehenden Welt-Hepatitis-Tags am 28. Juli eine Intensivierung der Behandlung und Präventionvon bestimmten Infektionskrankheiten – auch weil die Insassen nach ihrer Entlassung die Ausbreitung in der Allgemeinbevölkerung fördern könnten. (aerzteblatt.de, 26.07.2018)


FREE WEBINAR: How to deliver effective opioid substitute treatment in prisons - Monday 10th December 7 p.m.

How to deliver effective opioid substitute treatment in prisons

This webinar will focus on:

- overcoming organisational and cultural issues,

- stabilisation and assisted withdrawal,

- retox and continuity of care

Dr Joss Bray - Clinical Lead for Drug and Alcohol Treatment in the North East Prisons for Spectrum CIC.
Dr Jake Hard - HMP Eastwood Park and HMP Leyhill, Hanham Health surgery. Chair of the RCGP Secure Environments Group.
Tamara Healey - Non-Medical Prescriber, Substance Misuse, Eastwood Park Prison, Bristol Community Health. (SMMGP - Supporting good practice in drug and alcohol treatment, UK, 05.11.2018)


Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use

Michael Curtis, Paul Dietze, Campbell Aitken, Amy Kirwan, Stuart A. Kinner, Tony Butler and Mark Stoové

Harm Reduction Journal 2018, 15:48, doi.org/10.1186/s12954-018-0255-5


Schadensmindernde Maßnahmen beim intravenösen Drogenkonsum im Strafvollzug (Deutscher Bundestag. Drucksache19/5225, 19. Wahlperiode, 19.10.2018)

Antwort der Bundesregierung auf die Kleine Anfrage der Abgeordneten Niema Movassat, Dr. André Hahn, Gökay Akbulut, weiterer Abgeordneter und der Fraktion DIE LINKE. 

– Drucksache 19/4712 – 

Schadensmindernde Maßnahmen beim intravenösen Drogenkonsum im Strafvollzug 


USA. Rehabilitation Plus Rehab? Jails Dispense Drugs To Treat Inmates’ Addictions

At a time when the U.S. government is trying to deal with a nationwide opioid epidemic, many jails across the country are only now rolling out medicines to help inmates overcome addiction. And most of those jails dispense only one of the drugs currently available. (KHN – Kaiser Health News, 19.08.2018)


Suchtbehandlung im Vollzug: Ministerium weicht Fragen zur Opioid-Substitution im Gefängnis aus

Erhalten Opioid-Abhängige in deutschen Gefängnissen eine leitliniengerechte Behandlung? Danach erkundigte sich vor einigen Tagen die Linksfraktion im Bundestag in einer Kleinen Anfrage. Die meisten Teilfragen zur Versorgungssituation ließ das Bundesministerium für Justiz und Verbraucherschutz unbeantwortet. (DAZ – Deutsche Apotheker Zeitung, 22.10.2018)


Public health guidance on prevention and control of blood-borne viruses in prison settings

ECDC, EMCDDA,Lissabon,July 2018


USA. At Rikers Island, a Legacy of Medication-Assisted Opioid Treatment 

NEW YORK — For Dr. Ross MacDonald, every person who enters New York City’s main jail with an opioid addiction represents an opportunity for treatment, and the possibility of saving a life. 

As the medical director of the city’s correctional health program, he ensures that offenders who come in on methadone continue to receive it. And he and his staff try to persuade as many addicted inmates as possible to get started on methadone before they leave the jail. (Pew Trust, USA, 23.05.2016)


High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns.

Murphy PN, Mohammed F, Wareing M, Cotton A, McNeill J, Irving P, Jones S, Sharples L, Monk R, Elton P.

J Subst Abuse Treat. 2018 Sep;92:91-98. doi: 10.1016/j.jsat.2018.07.002.



Incarceration, drug use, and infectious diseases: a syndemic still not addressed

Zaller, Nickolas et al.

The Lancet Infectious Diseases , Volume 0 , Issue 0 , 

Published:October 29, 2018, doi.org/10.1016/S1473-3099(18)30538-3


UK. High risk strategy - Failure to provide naloxone at the point of release for most prisoners is putting lives at risk, says John Jolly.

Those leaving prison having had an opiate problem are seriously at risk of having a life-threatening overdose or dying as a result of one. Both Public Health England (PHE) and the government have been clear in their recommendation that all local areas need to have appropriate naloxone provision in place. However, prisons have so far failed to implement provision at the point of release across much of the estate, and this is putting lives at risk. (DDN – Drink and Drugs News, UK, 09.07.2018)


Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

Stone, Jack et al.

The Lancet Infectious Diseases , Volume 0 , Issue 0 , Published: October 29, 2018, doi.org/10.1016/S1473-3099(18)30469-9


Naloxone-on-Release - Guidelines for naloxone provision upon release from custodial settings.

(...) The project, led by the Frankfurt University of Applied Science, received funding from the European Union for the period 2017-2018. It aims at addressing the gaps in the continuity of care for long-term drug users in prison and upon release, by supporting life-saving interventions for the prevention of overdoses and reduction of other risks related to drug use and for the establishment of a treatment path, which does not get interrupted upon release.

(Frankfurt University of Applied Science und ISFF – Institut für Suchtforschung Frankfurt, 2018)


USA. Pennsylvania DOC to Pilot Injectable Buprenorphine for Detoxing Prisoners

The Pennsylvania Department of Corrections is moving to reduce Suboxone diversion in its prisons by giving inmates suffering from opioid withdrawal an injectable form of the treatment drug buprenorphine. The plan may even make a dent in the state’s annual toll of more than 5,000 overdose deaths. (Filter, USA, 12.10.2018)


“My first 48 hours out” – comprehensive approaches to pre and post prison release interventions for drug users in the criminal justice system” 

For prisoners with a history of drug use, in particular opioid use, the risks related to drug use, in particular overdose and death are extremely high in the immediate period after release due to high rates of relapse and lower opioid tolerance. Much still needs to be done in order to ensure that people with a severe history of drug use are sufficiently cared for, when released from prisons. Harm reduction measures need to be in place for ex-prisoners to be able to readjust to freedom without relapsing back into drug use and extreme risk of fatal overdose when released.


Rheinland-Pfalz will Designerdrogen im Gefängnis aufspüren

Ein Brief mit Kokain, Methadon in Augentropfen oder eine Designerdroge im Papier: Drogen finden auf unterschiedlichste Weise in den Knast. Das will die JVA Wittlich gemeinsam mit dem Justizministerium und dem LKA in Rheinland-Pfalz verhindern. (Welt, 17.10.2018)


Naloxone. "My first 48 hours out“ - Comprehensive approaches to pre and post prison release interventions for drug users in the criminal justice system

Projektbeschreibung: For prisoners with a history of drug use, in particular opioid use, the risks related to drug use, in particular overdose and death are extremely high in the immediate period after release due to high rates of relapse and lower opioid tolerance (Farrell and Marsden, 2008). Much still needs to be done in order to ensure that people with a severe history of drug use are sufficiently cared for, when released from prisons. Harm reduction measures need to be in place for ex-prisoners to be able to readjust to freedom without relapsing back into drug use and extreme risk of fatal overdose when released. 

The immediate time after release (“my first 48 hours out”) is a critical time for action, when the cooperation between prisons, healthcare providers and NGOs is key in ensuring continuity of care and where targeted interventions can save lives from overdose and build a path towards engagement into further treatment and rehabilitation for drug users. (Frankfurt University for Applied Sciences, o.D.)


Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments.

Azbel L, Wegman MP, Polonsky M, Bachireddy C, Meyer J, Shumskaya N, Kurmanalieva A, Dvoryak S, Altice FL.

Int J Prison Health. 2018 Sep 10;14(3):175-187. doi: 10.1108/IJPH-03-2017-0016.



Große Unterschiede bei HIV- und HCV-Behandlung sowie Opioid-Substitutions-Therapie unter Gefangenen in Deutschland

Erstmals gibt es eine Studie, die aus Sekundärdaten die Arzneimittelversorgung von Inhaftierten mit einer HIV-, HCV-Infektion oder Opioidabhängigkeit in Justizvollzugsanstalten (JVAen) in verschiedenen Bundesländern beschreibt und bewertet. Das Ergebnis: Die Behandlung dieser Krankheiten in JVAen wird zwar leitliniengerecht durchgeführt, aber zum Teil große Unterschiede zeigten sich beim Anteil der Behandelten pro JVA-Population für die untersuchten Krankheiten und zwischen den Bundesländern.

(Deutschsprachige Kurzfassung der Publikation Müller J. et al.: High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany. BMC Public Health 2017; 17(1): 843. DOI: 10.1186/s12889-017-4840-4)


Pakistan’s HIV Epidemic and the Need for Prison-Based Harm Reduction Programmes

Faryal Sajjad

GDPO Situation Analysis, October 2018


EMCDDA. New psychoactive substances in prison (Video)

The use of new psychoactive substances (NPS) among prisoners appears to be a rapidly developing phenomenon. But empirical data are currently scarce and patchy. A recent study suggests that synthetic cannabinoids are the most common group of NPS used in prison. (EMCDDA, Lissabon, 07.06.2018, Video, 01:37)


European evidence-based guidance on prevention and control of HCV in prison settings (poster)


In the 31 EU/EEA countries, more than 590 000 persons are held in a custodial facility on any given day. According to recent reviews of prison studies from EU countries, prison prevalence estimates for HCV ranged from 4.3 % to 86.3 %.

People in prison also tend to have multiple complex health and social care needs resulting from a mix  of specific socio-economic determinants and environmental factors. A significant proportion of people in prison have a history of drug use, and a strong association has been found between prison history and HCV prevalence in people who inject drugs.

Prisons are settings of increased risk for HCV transmission, while representing a unique opportunity to address the healthcare needs of those people in prison who belong to hard-to-reach and medically underserved groups in the community, such as people who inject drugs. (EMCDDA,ECDC,Lisasbon,September 2018)